PE20131128A1 - Metodo de produccion de un compuestos intermediario para sintetizar un medicamento - Google Patents

Metodo de produccion de un compuestos intermediario para sintetizar un medicamento

Info

Publication number
PE20131128A1
PE20131128A1 PE2013000351A PE2013000351A PE20131128A1 PE 20131128 A1 PE20131128 A1 PE 20131128A1 PE 2013000351 A PE2013000351 A PE 2013000351A PE 2013000351 A PE2013000351 A PE 2013000351A PE 20131128 A1 PE20131128 A1 PE 20131128A1
Authority
PE
Peru
Prior art keywords
compound
synthesize
production method
formula
medicinal product
Prior art date
Application number
PE2013000351A
Other languages
English (en)
Inventor
Bong Chan Kim
Kyu Young Kim
Hee Bong Lee
Ji Eun An
Kyu Woong Lee
Original Assignee
Lg Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Life Sciences Ltd filed Critical Lg Life Sciences Ltd
Publication of PE20131128A1 publication Critical patent/PE20131128A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

REFERIDA A UN METODO DE PREPARACION DE UN COMPUESTO DE FORMULA (2) QUE COMPRENDE: a) UNA REACCION DE ACOPLAMIENTO POR ADICION DE UNA BASE TAL COMO TRIALQUILAMINA C1-C4 AL COMPUESTO DE FORMULA (4) Y FORMULA (5), b) CICLAR POR ADICION DE UN ACIDO TAL COMO ACIDO ACETICO PARA OBTENER EL COMPUESTO (2a), c) HIDROLIZAR EL COMPUESTO (2a) PARA OBTENER EL COMPUESTO (2), DONDE R3, R4, R5 Y R6 SON H, HALOGENO, ALQUILO C1-C4, ENTRE OTROS; P1 ES UN PROTECTOR DE AMINA TAL COMO BUTILOXICARBONILO; P2 Y P3 SON BENCILO, METILO, ETILO, ENTRE OTROS; G1O ES TRIFLATO, MESILATO, TOSILATO, BESILATO O NONAFLATO. DICHO PROCEDIMIENTO ES UTIL EN LA PREPARACION DE COMPUESTOS INTERMEDIARIOS PARA LA ELABORACION DE UN COMPUESTO QUE TIENE ACTIVIDAD INHIBITORIA CONTRA LA ENZIMA DIPEPTIDIL PEPTIDASA IV
PE2013000351A 2010-09-03 2011-08-25 Metodo de produccion de un compuestos intermediario para sintetizar un medicamento PE20131128A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20100086619 2010-09-03

Publications (1)

Publication Number Publication Date
PE20131128A1 true PE20131128A1 (es) 2013-10-18

Family

ID=45023417

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013000351A PE20131128A1 (es) 2010-09-03 2011-08-25 Metodo de produccion de un compuestos intermediario para sintetizar un medicamento

Country Status (32)

Country Link
US (1) US8741927B2 (es)
EP (1) EP2611776B1 (es)
JP (1) JP5705985B2 (es)
KR (1) KR101378984B1 (es)
CN (1) CN103080088B (es)
AP (1) AP3270A (es)
AR (1) AR082881A1 (es)
AU (1) AU2011296767B2 (es)
BR (1) BR112013004988B1 (es)
CA (1) CA2810393C (es)
CL (1) CL2013000589A1 (es)
CO (1) CO6700826A2 (es)
DK (1) DK2611776T3 (es)
EA (1) EA022500B1 (es)
EC (1) ECSP13012471A (es)
ES (1) ES2607089T3 (es)
HK (1) HK1184787A1 (es)
HU (1) HUE032484T2 (es)
IL (1) IL224954B (es)
MA (1) MA34490B1 (es)
MX (1) MX2013002277A (es)
MY (1) MY157423A (es)
NZ (1) NZ607694A (es)
PE (1) PE20131128A1 (es)
PL (1) PL2611776T3 (es)
PT (1) PT2611776T (es)
SG (1) SG188329A1 (es)
SI (1) SI2611776T1 (es)
TW (1) TWI438188B (es)
UA (1) UA107721C2 (es)
UY (1) UY33589A (es)
WO (1) WO2012030106A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2995612A1 (en) * 2014-09-12 2016-03-16 Université de Strasbourg Novel non-natural amino acids, their process of preparation and uses thereof
KR102068754B1 (ko) * 2017-04-20 2020-01-21 주식회사 엘지화학 의약품 합성용 중간체 화합물의 제조 방법
PE20201169A1 (es) * 2017-09-28 2020-10-28 Lg Chemical Ltd Metodo de produccion de un compuesto intermedio para sintetizar un medicamento
WO2019066578A1 (ko) * 2017-09-28 2019-04-04 주식회사 엘지화학 의약품 합성용 중간체 화합물의 제조 방법
MX2020005099A (es) * 2017-11-16 2020-08-13 Lg Chemical Ltd Metodo de produccion de un compuesto intermedio para sintetizar un medicamento.
KR102184129B1 (ko) * 2017-11-16 2020-11-27 주식회사 엘지화학 의약품 합성용 중간체 화합물의 제조 방법
CN113861061A (zh) * 2021-10-25 2021-12-31 成都市科隆化学品有限公司 一种不含无机铵盐的氨基酸酰胺盐酸盐及其合成方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4456768A (en) * 1980-10-08 1984-06-26 The University Of Chicago Chemical synthesis
US5556982A (en) 1985-01-14 1996-09-17 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
DE3705272A1 (de) * 1987-02-19 1988-09-01 Basf Ag Verfahren zur reduktion von mono- und dicarbonsaeuren
US5417023A (en) * 1993-12-27 1995-05-23 Mandish; Theodore O. Building panel apparatus and method
IL151018A0 (en) * 2000-03-17 2003-02-12 Bristol Myers Squibb Pharma Co Beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha
TWI357902B (en) 2005-04-01 2012-02-11 Lg Life Science Ltd Dipeptidyl peptidase-iv inhibiting compounds, meth
EA200970189A1 (ru) * 2006-08-09 2009-08-28 Смитклайн Бичам Корпорейшн Пирролидинонанилины как модуляторы прогестероновых рецепторов
KR20080071476A (ko) * 2007-01-30 2008-08-04 주식회사 엘지생명과학 신규한 디펩티딜 펩티데이즈 ｉｖ(ｄｐｐ-ｉｖ) 저해제
BRPI0819719B8 (pt) * 2007-12-21 2021-05-25 Lg Chemical Ltd compostos de inibição de dipeptidil peptidase-iv, métodos de preparação dos mesmos, e preparações farmacêuticas contendo os mesmos como agente ativo

Also Published As

Publication number Publication date
EA201390336A1 (ru) 2013-07-30
CN103080088B (zh) 2014-09-24
PL2611776T3 (pl) 2017-06-30
AP2013006763A0 (en) 2013-03-31
WO2012030106A3 (en) 2012-05-18
NZ607694A (en) 2015-08-28
HK1184787A1 (en) 2014-01-30
AU2011296767A1 (en) 2013-03-14
CA2810393A1 (en) 2012-03-08
CO6700826A2 (es) 2013-06-28
ECSP13012471A (es) 2013-04-30
PT2611776T (pt) 2016-12-20
SG188329A1 (en) 2013-04-30
CN103080088A (zh) 2013-05-01
CL2013000589A1 (es) 2013-07-12
HUE032484T2 (en) 2017-09-28
TW201213297A (en) 2012-04-01
SI2611776T1 (sl) 2017-03-31
US20130165659A1 (en) 2013-06-27
BR112013004988B1 (pt) 2020-07-28
BR112013004988A2 (pt) 2016-05-31
JP2013543484A (ja) 2013-12-05
CA2810393C (en) 2016-04-12
MX2013002277A (es) 2013-05-22
EA022500B1 (ru) 2016-01-29
TWI438188B (zh) 2014-05-21
JP5705985B2 (ja) 2015-04-22
UA107721C2 (ru) 2015-02-10
IL224954B (en) 2018-11-29
KR101378984B1 (ko) 2014-03-27
US8741927B2 (en) 2014-06-03
AR082881A1 (es) 2013-01-16
AU2011296767B2 (en) 2015-04-23
DK2611776T3 (en) 2017-01-09
MY157423A (en) 2016-06-15
ES2607089T3 (es) 2017-03-29
EP2611776B1 (en) 2016-09-21
MA34490B1 (fr) 2013-08-01
UY33589A (es) 2011-12-01
AP3270A (en) 2015-05-31
WO2012030106A2 (en) 2012-03-08
EP2611776A2 (en) 2013-07-10
EP2611776A4 (en) 2014-08-20
KR20120060139A (ko) 2012-06-11

Similar Documents

Publication Publication Date Title
PE20131128A1 (es) Metodo de produccion de un compuestos intermediario para sintetizar un medicamento
NZ701626A (en) Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
EA201490320A1 (ru) Соединения тетрагидропиридопиридина и тетрагидропиридопиримидина и их применение в качестве модуляторов рецептора c5a
PE20130385A1 (es) Derivados del acido naft-2-ilacetico para tratar el sida
MX351305B (es) Antagonistas del receptor de mineralocorticoides.
PH12015500457A1 (en) Alkoxy pyrazoles as soluble guanylate cyclase activators
UY33950A (es) Inhibidores de benzodioxano de la producciòn de leucotrieno
MX2009009238A (es) Nuevos inhibidores de fosfodiesterasa.
MY170922A (en) Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives
PE20141554A1 (es) Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, procedimientos para su preparacion, preparados farmaceuticos que los contienen, asi como su uso para la preparacion de medicamentos
MY152281A (en) 4-pyrimidinesulfamide derivative
CY1116721T1 (el) Νεες ενωσεις ως προσδεματα υποδοχεων ισταμινης η3
BR112015011974A8 (pt) derivados de azaquinazolina carboxamida, seus usos e processo para sua produção, medicamento e composição farmacêutica
CU20120064A7 (es) Nueva asociación entre la 4-{3-[cis-hexahidrociclopenta[c]pirrol-2(1h)-il]propoxi}benzamida y un inhibidor de la acetilcolinesterasa y las composiciones farmacéuticas que la contienen
MA35188B1 (fr) Tétrahydroquinolines à fusion cycloalkyle en tant que modulateurs de l'activité du récepteur crth2
BR112012017845A2 (pt) novo processo para produção de derivados de benzofenona
PE20140629A1 (es) Derivados de fenil-isoxazol y procedimiento para la preparacion de los mismos
EA201300647A1 (ru) Оптимизированный синтез чистых неполиморфных кристаллических жёлчных кислот с заданным размером частиц
CY1116739T1 (el) Μεθοδος συνθεσης και κρυσταλλικη μορφη του υδροχλωρικου 4-{3-[cis-εξαϋδροκυκλοπεντα[c]πυρρολ-2(1η)-υλ] προποξυ} βενζαμιδιου καθως και η συνδεομενη ελευθερη βαση και οι φαρμακευτικες συνθεσεις οι οποιες τις περιεχουν
ECSP13012548A (es) Inhibidores de oxadiazol de la producción de leucotrienos.
BRPI0821611A8 (pt) Derivado de 3-carboxipropil-aminotetralina e compostos relacionados como antagonistas do receptor opióide mu
MX2010009926A (es) Nuevo proceso para la preparacion de derivados de acido ciclohexancarboxilico.
MX2010009876A (es) Nuevo proceso para la preparacion de derivados de acido ciclohexanocarboxilico por medio del derivado de ciclohexanocarboxamida correspondiente.
PE20150154A1 (es) N-[4-(quinolin-4-iloxi)ciclohexil(metil)](hetero)arilcarboxamidas como antagonistas del receptor de androgenos, su produccion y usos como productos medicinales
MY164880A (en) Process for the preparation of isoxazolyl-methoxy-nicotinic acids

Legal Events

Date Code Title Description
FG Grant, registration